{
    "clinical_study": {
        "@rank": "124462", 
        "acronym": "RECOIL", 
        "arm_group": {
            "arm_group_label": "Bronchoscopic lung volume reduction", 
            "arm_group_type": "Experimental", 
            "description": "Bronchoscopic lung volume reduction with the RePneu Lung Volume Reduction Coil system"
        }, 
        "brief_summary": {
            "textblock": "Rationale:\n\n      The combined data from 3 studies outside the Unites States investigating the Lung Volume\n      Reduction Coil system (RePneu LVRC) showed statistically significant improvements in\n      pulmonary function, exercise capacity and quality of life at both 6-Months and 12-Months\n      post treatment. 24 months post treatment the improved pulmonary function and exercise\n      capacity are slightly decreasing. Retreating the patient with the LVR coil system in other\n      parts of the lung could potentially lead to new improvements in lung function, dyspnea,\n      exercise capacity and quality of life and may reduce the rate of decline.\n\n      Objective:\n\n      To investigate the safety and feasibility of re-treating patients with severe Chronic\n      Obstructive Pulmonary Disease (COPD) with the RePneu LVRC system."
        }, 
        "brief_title": "A Safety and Feasibility Study of Re-treating Patients With Severe Emphysema With the RePneu LVRC System.", 
        "completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "COPD", 
            "Emphysema"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Emphysema", 
                "Pulmonary Emphysema", 
                "Pulmonary Disease, Chronic Obstructive"
            ]
        }, 
        "detailed_description": {
            "textblock": "Rationale:\n\n      The combined data from 3 studies outside the Unites States investigating the Lung Volume\n      Reduction Coil system (RePneu LVRC) showed statistically significant improvements in\n      pulmonary function, exercise capacity and quality of life at both 6-Months and 12-Months\n      post treatment. 24 months post treatment the improved pulmonary function and exercise\n      capacity are slightly decreasing. Retreating the patient with the LVR coil system in other\n      parts of the lung could potentially lead to new improvements in lung function, dyspnea,\n      exercise capacity and quality of life and may reduce the rate of decline.\n\n      Objective:\n\n      To investigate the safety and feasibility of re-treating patients with severe Chronic\n      Obstructive Pulmonary Disease (COPD) with the RePneu LVRC system.\n\n      Study design:\n\n      This study is a non randomized uncontrolled intervention.\n\n      Study population: Patients with severe emphysema who have previously been treated with the\n      lung volume reduction coil system and significantly improved in lung function, exercise\n      capacity or quality of life, 6 months after the treatment.\n\n      Intervention:\n\n      Patients will receive a lung volume reduction coil treatment by bronchoscopy.\n\n      Main study parameter:\n\n      The safety objective of this study is to identify the potential number and type of\n      device-related and procedure-related adverse effects.\n\n      Secondary study parameters:\n\n      Lung function\n\n        -  Change in RV, 6 months following treatment\n\n        -  Change in RV/TLC ratio, 6 months following treatment\n\n        -  Changes in FEV1 and FVC, 2 and 6 months following treatment\n\n      Quality of life\n\n        -  Change in the SGRQ score, 2 and 6 months following treatment\n\n        -  Change in the CCQ score, 2 and 6 months following treatment\n\n      Functional measures\n\n        -  Change in the mMRC score, 2 and 6 months following treatment\n\n        -  Change in the 6MWD, 2 and 6 months following treatment"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Treated with the RePneu LVRC system > 24 months ago.\n\n          2. Six months after the first bilateral treatment with the RePneu LVRC system the\n             patient had a significant improvement above the established minimal important\n             difference (MID) of 6-minute walk distance (6MWD: 26 meter) or of forced expiratory\n             volume in 1 second (FEV1: 100ml) or of St. Georges Respiratory Questionnaire total\n             score (SGRQ: 4 points).\n\n          3. Subject has marked dyspnea scoring \u22652 on mMRC scale of 0-4.\n\n          4. Subject has stopped smoking for at least 6 months prior to entering the study.\n\n          5. Subject read, understood and signed the Informed Consent form.\n\n          6. Subject has completed a pulmonary rehabilitation program within 6 months prior to\n             treatment and/or regularly performing maintenance respiratory rehabilitation if\n             initial supervised therapy occurred more than 6 months prior to baseline testing.\n\n          7. Subject has received Influenza vaccinations consistent with local recommendations\n             and/or policy.\n\n        Exclusion Criteria:\n\n          1. Subject has co-morbidities that may significantly reduce subject's ability to improve\n             exercise capacity (e.g., severe arthritis, planned knee surgery) or baseline\n             limitation on 6MWT is not due to dyspnea.\n\n          2. Subject has severe gas exchange abnormalities as defined by:\n\n             PaCO2 >8.0 kPa; PaO2 < 6.0 kPa (room air).\n\n          3. Subject has a history of recurrent clinically significant respiratory infections,\n             defined as 3 hospitalizations for respiratory infection during the year prior to\n             enrollment.\n\n          4. Subject has severe pulmonary hypertension defined by right ventricular systolic\n             pressure >50 mm Hg via echocardiogram.\n\n          5. Subject has an inability to walk >140 meters in 6 minutes.\n\n          6. Subject has evidence of other severe disease (such as, but not limited to, lung\n             cancer or renal failure), which in the judgment of the investigator may compromise\n             survival of the subject for the duration of the study.\n\n          7. Subject is pregnant or lactating, or plans to become pregnant within the study\n             timeframe.\n\n          8. Subject has an inability to tolerate bronchoscopy under moderate sedation or general\n             anesthesia.\n\n          9. Subject has clinically significant bronchiectasis.\n\n         10. Subject has giant bullae >1/3 lung volume.\n\n         11. Subject has had previous LVR surgery, lung transplantation or lobectomy.\n\n         12. Subject has been involved in pulmonary drug or device studies within 30 days prior to\n             this study.\n\n         13. Subject is taking >20 mg prednisone (or equivalent dose of a similar steroid) daily.\n\n         14. Subject requires high level chronic immunomodulatory therapy to treat a moderate to\n             severe chronic inflammatory autoimmune disorder.\n\n         15. Subject is on an antiplatelet (such as Plavix) or anticoagulant therapy (such as\n             heparin or Coumadin) which cannot be stopped for 7 days prior to procedure.\n\n         16. Subject has a sensitivity or allergy to Nickel.\n\n         17. Subject has a known sensitivity to drugs required to perform bronchoscopy.\n\n         18. Subject has any other disease, condition(s) or habit(s) that would interfere with\n             completion of study and follow up assessments, would increase risks of bronchoscopy\n             or assessments, or in the judgment of the investigator would potentially interfere."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02012673", 
            "org_study_id": "RECOIL-study"
        }, 
        "intervention": {
            "arm_group_label": "Bronchoscopic lung volume reduction", 
            "description": "Bronchoscopic lung volume reduction with the RePneu Lung Volume Reduction Coil system. The RePneu LVRC is an implantable device, delivered through a fiber-optic bronchoscope, designed specifically to treat patients suffering from emphysema. The Coil is intended to compress the most damaged parenchyma and tension the surrounding tissue, which increases elastic recoil, reduces hyperinflation and redirects air to healthier portions of the lung for more effective ventilation.", 
            "intervention_name": "Bronchoscopic lung volume reduction", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "COPD", 
            "Emphysema", 
            "Bronchoscopy", 
            "Lung Volume Reduction"
        ], 
        "lastchanged_date": "January 27, 2014", 
        "link": {
            "description": "Website of the bronchoscopic intervention center of the UMCG", 
            "url": "http://www.bronchoscopie.umcg.nl"
        }, 
        "location": {
            "contact": {
                "email": "k.klooster@umcg.nl", 
                "last_name": "Karin Klooster", 
                "phone": "+31503616161"
            }, 
            "facility": {
                "address": {
                    "city": "Groningen", 
                    "country": "Netherlands"
                }, 
                "name": "University Medical Center Groningen"
            }, 
            "investigator": {
                "last_name": "Dirk-Jan Slebos, MD PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "1", 
        "official_title": "The Safety and Feasibility of Re-treating Patients With Severe Emphysema With the RePneu LVRC System: a Pilot Study.", 
        "overall_contact": {
            "email": "k.klooster@umcg.nl", 
            "last_name": "Karin Klooster, Coordinator", 
            "phone": "+31503616161"
        }, 
        "overall_official": {
            "affiliation": "University Medical Center Groningen, Department of Pulmonary Diseases", 
            "last_name": "Dirk-Jan Slebos, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Netherlands: CCMO and Medical Ethics Review Committee (METC)", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The safety objective of this study is to identify the potential number and type of device-related and procedure-related adverse effects.", 
            "measure": "Number and type of adverse effects as a measure of safety between baseline and 6 months follow up", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline - 6 month follow up"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02012673"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Medical Centre Groningen", 
            "investigator_full_name": "Dirk-Jan Slebos", 
            "investigator_title": "MD PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "-Changes in FEV1 and FVC, 2 months following treatment", 
                "measure": "Change from Baseline in Lung function at 2 months", 
                "safety_issue": "No", 
                "time_frame": "Baseline vs 2 month  follow up"
            }, 
            {
                "description": "Change in the SGRQ score, 2 months following treatment\nChange in the CCQ score, 2 months following treatment", 
                "measure": "Change from Baseline in Quality of life at 2 months", 
                "safety_issue": "No", 
                "time_frame": "Baseline vs 2 month follow up"
            }, 
            {
                "description": "Change in the mMRC score, 2 months following treatment\nChange in the 6MWD, 2 months following treatment", 
                "measure": "Change from Baseline in functional measures at 2 months", 
                "safety_issue": "No", 
                "time_frame": "Baseline vs 2 month  follow up"
            }, 
            {
                "description": "Change in RV, 6 months following treatment\nChange in RV/TLC ratio, 6 months following treatment\nChanges in FEV1 and FVC, 6 months following treatment", 
                "measure": "Change from Baseline in Lung function at 6 months", 
                "safety_issue": "No", 
                "time_frame": "Baseline vs  6 month follow up"
            }, 
            {
                "description": "Change in the SGRQ score, 6 months following treatment\nChange in the CCQ score, 6 months following treatment", 
                "measure": "Change from Baseline in quality of life at 6 months", 
                "safety_issue": "No", 
                "time_frame": "Baseline vs 6 month follow up"
            }, 
            {
                "description": "Change in the mMRC score, 6 months following treatment\nChange in the 6MWD, 6 months following treatment", 
                "measure": "Change from Baseline in functional measures at 6 months", 
                "safety_issue": "No", 
                "time_frame": "Baseline vs 6 month follow up"
            }
        ], 
        "source": "University Medical Centre Groningen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Medical Centre Groningen", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}